Q2 EPS Estimates for iTeos Therapeutics Reduced by Wedbush

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Analysts at Wedbush reduced their Q2 2025 EPS estimates for shares of iTeos Therapeutics in a research note issued to investors on Wednesday, May 28th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($1.48) per share for the quarter, down from their prior forecast of ($0.85). Wedbush has a "Neutral" rating and a $12.00 price objective on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics' Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($3.17) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.08) EPS.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14.

Several other equities research analysts have also weighed in on ITOS. Leerink Partnrs lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. Piper Sandler reiterated an "overweight" rating and issued a $12.00 target price (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $12.00 target price (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Finally, Leerink Partners reiterated a "market perform" rating and issued a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $15.86.

iTeos Therapeutics Trading Up 2.5%

Shares of iTeos Therapeutics stock traded up $0.25 during midday trading on Friday, reaching $10.26. The company had a trading volume of 494,003 shares, compared to its average volume of 817,406. iTeos Therapeutics has a 1-year low of $4.80 and a 1-year high of $18.13. The company has a market capitalization of $392.69 million, a price-to-earnings ratio of -3.26 and a beta of 1.39. The stock has a fifty day simple moving average of $7.06 and a 200 day simple moving average of $7.40.

Hedge Funds Weigh In On iTeos Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ITOS. Balyasny Asset Management L.P. acquired a new position in iTeos Therapeutics in the 4th quarter valued at approximately $218,000. Empowered Funds LLC increased its position in shares of iTeos Therapeutics by 5.0% during the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock worth $530,000 after buying an additional 3,305 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of iTeos Therapeutics during the fourth quarter worth $461,000. Virtu Financial LLC increased its position in shares of iTeos Therapeutics by 84.3% during the fourth quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock worth $142,000 after buying an additional 8,460 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in iTeos Therapeutics in the fourth quarter worth $142,000. Institutional investors own 97.16% of the company's stock.

Insider Buying and Selling at iTeos Therapeutics

In other iTeos Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of iTeos Therapeutics stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider now owns 2,108,594 shares in the company, valued at $16,995,267.64. The trade was a 23.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of iTeos Therapeutics stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now owns 3,452,797 shares of the company's stock, valued at $27,829,543.82. This trade represents a 23.01% decrease in their position. The disclosure for this sale can be found here. Company insiders own 12.50% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.